Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02759289 · ClinicalTrials.gov registry record
Arsenic, Disordered Glucose Homeostasis and Atherosclerosis
A clinical trial, sponsored by NYU Langone Health.
- Completed
- Registry status
- 279
- Enrollment target
NCT02759289 is a clinical trial that has completed, run by NYU Langone Health. The registered enrollment target is 279 participants.
The verdict
NCT02759289 has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- 279 participants
- Enrollment target
Study Summary
Investigators will recruit 250 subjects; Group A will consist of 100 prediabetic patients with an A1c of 5.7%-6.4%. Group B will consist of 100 patients with uncontrolled T2D defined as either a) an A1c of 6.5%-7.9% without diabetes medications or b) an A1c ≥ 8.0% with or without diabetes medications. Group C will include 50 participants without T2D or known cardiovascular disease to serve as control comparisons.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 279 participants |
| Start Date | 2015-11 |
| Est. Completion | 2020-09-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02759289
The ClinicalTrials.gov registry entry for NCT02759289 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 279 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02759289 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02759289 about?
NCT02759289 is a clinical study titled "Arsenic, Disordered Glucose Homeostasis and Atherosclerosis". Investigators will recruit 250 subjects; Group A will consist of 100 prediabetic patients with an A1c of 5.7%-6.4%. Group B will consist of 100 patients with uncontrolled T2D defined as either a) an A1c of 6.5%-7.9% without diabetes medications or b) an A1c ≥ 8.0% with or without diabetes medication...
What is the current status of trial NCT02759289?
This trial is currently completed. The enrollment target is 279 participants. The study started on 2015-11. Estimated completion is 2020-09-15.
Who is sponsoring clinical trial NCT02759289?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.